So-called “public health” authorities are routinely misleading parents about the risks of getting their children jabbed with COVID-19 vaccines, including with outright lies about what we know from scientific research.
Last month, I published a video showing how Munson Healthcare is deceiving parents in northern Michigan about the benefits versus risks of COVID-19 vaccines. Last week, with a particular focus on children aged five to eleven, I published a video similarly showing how the Michigan Department of Health and Human Services (MDHHS) is deceiving parents, including by deceiving that vaccines authorized for emergency use have undergone the same standards of study and regulatory review as FDA approved products and lying that vaccination even of children who’ve already recovered from infection is necessary because the scientific evidence suggests that natural immunity is short-lived.
In this third video, which follows up directly on the second, I continue to show how MDHHS is outright lying to parents, including by lying that the spike protein from SARS-CoV-2 by itself is “harmless” and claiming that the risk of myocarditis from SARS-CoV-2 infection is greater than the risk of myocarditis from COVID-19 when their own primary source data shows the opposite. Topics I cover and deceptions I expose in this video include:
- How MDHHS claims that children with immune-compromising conditions may safely receive the COVID-19 vaccine even though immune-compromised children were excluded from Pfizer’s clinical trial.
- How MDHHS claims that the COVID-19 vaccines induce cells to produce a “harmless” spike protein of SARS-CoV-2, the virus that causes COVID-19, even though the scientific literature shows that the spike protein alone is pathogenic.
- How MDHHS claims that “there is no way to tell in advance if your child will get a severe or mild case” of COVID-19 even though risk factors for severe disease are well defined in the scientific literature.
- How CDC data shows that the absolute risk of hospitalization with COVID-19 for the childhood population during the study period was 0.008%.
- How estimates of “COVID-19” hospitalizations for children inflate the numbers by counting children who went to the hospital for other reasons and only incidentally tested positive.
- How MDHHS states that “There were zero cases of myocarditis in children ages 5-11 years during clinical trials” as though this offers reassurance that the benefits outweigh the risks when in fact the trial was not powered to be able to determine the risk.
- How MDHHS claims that COVID-19 vaccines are “safe” for children who someday might want to have a baby even though there were no human studies assessing the effects of the vaccines on fertility.
- How MDHHS states that “The risk of myocarditis from COVID-19 infection appears to be greater than the risk of myocarditis from COVID-19 vaccination”, when in fact the data from its own primary sources cited show precisely the opposite.
Sources
Michigan State Government, “COVID-19 Vaccine Questions and Answers for Parents,” Michigan.gov, November 3, 2021, accessed December 7, 2021, https://www.michigan.gov/documents/coronavirus/Parent_FAQs_5.14_Final_725378_7.pdf.
Jeremy R. Hammond, “How ‘Public Health’ Officials Lie to Parents about COVID-19 Vaccines for 5-11 Year-Old Children”, JeremyRHammond.com, December 8, 2021, https://www.jeremyrhammond.com/2021/12/08/how-public-health-officials-lie-to-parents-about-covid-19-vaccines-for-5-11-year-old-children/.
Lindsay Kim et al., “Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 1–July 25, 2020”, MMWR, August 7, 2020, http://dx.doi.org/10.15585/mmwr.mm6932e3. (Describes risk factors for severe disease in children and enables calculation of hospitalization rate of 1 child per 12,500 childhood population.)
Emmanuel B. Walter et al., “Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,” New England Journal of Medicine, November 9, 2021, https://doi.org/10.1056/NEJMoa2116298. (Pfizer’s clinical trial data used to obtain emergency use authorization for children aged five to eleven.)
David A. Siegel et al., “Trends in COVID-19 Cases, Emergency Department Visits, and Hospital Admissions Among Children and Adolescents Aged 0–17 Years — United States, August 2020–August 2021”, MMWR, September 3, 2021, http://dx.doi.org/10.15585/mmwr.mm7036e1. (Estimates COVID-19 incidence during January 2021 peak at 30.1 children aged five to eleven per 100,000 persons. Acknowledges limitation that children in the hospital diagnosed with COVID-19 may not have been there because of COVID-19.)
Amy Beck and Monica Gandhi, “Adjudicating Reasons for Hospitalization Reveals That Severe Illness From COVID-19 in Children Is Rare”, Hospital Pediatrics, August 1, 2021, https://doi.org/10.1542/hpeds.2021-006084. (Reports finding that 40% of children in the hospital with COVID-19 were not there because of COVID-19.)
Tetyana P. Buzhdygan et al., “The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood–brain barrier”, Neurobiology of Disease, October 11, 2020, https://doi.org/10.1016/j.nbd.2020.105131. (Finds that SARS-CoV-2 spike protein promotes loss of blood-brain barrier integrity and triggers an inflammatory response on brain endothelial cells.)
Yuichiro J. Suzuki and Sergiy G. Gychka, “SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines”, Vaccines, January 11, 2021, https://doi.org/10.3390/vaccines9010036. (Notes that the pathogenicity of the spike protein is a relevant concern for COVID-19 vaccines.)
Yuyang Lei et al., “SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2”, Circulation Research, March 31, 2021, https://doi.org/10.1161/CIRCRESAHA.121.318902. (Shows that spike protein alone can damage vascular endothelial cells.)
Experimental Biology, “SARS-CoV-2 spike protein alone may cause lung damage”, EurekAlert!, April 27, 2021, https://www.eurekalert.org/news-releases/490426.
Pavel Solopov et al., “Single intratracheal exposure to SARS-CoV-2 S1 spike protein induces acute lung injury in K18-hACE2 transgenic mice”, The FASEB Journal, May 14, 2021, https://doi.org/10.1096/fasebj.2021.35.S1.04183.
Alana F. Ogata et al., “Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients”, Clinical Infectious Diseases, May 20, 2021, https://doi.org/10.1093/cid/ciab465. (Shows that spike protein induced by Moderna’s mRNA COVID-19 vaccine circulate throughout the body.)
Roxana Bruno et al., “SARS-CoV-2 mass vaccination: Urgent questions on vaccine safety that demand answers from international health agencies, regulatory authorities, governments and vaccine developers”, Authorea, May 24, 2021, https://doi.org/10.22541/au.162136772.22862058/v2. (Expresses concern that government authorities are minimizing or ignoring concerns about the potential toxicity and pathogenicity of the spike protein induced by vaccination.)
Biykem Bozkurt, Ishan Kamat, and Peter J. Hotez, “Myocarditis With COVID-19 mRNA Vaccines”, Circulation, July 20, 2021, https://doi.org/10.1161/CIRCULATIONAHA.121.056135. (Notes that mRNA COVID-19 vaccines can cause myocarditis and hypothesizes that this may be due to an autoimmune response induced by the presence of the spike protein.)
Bruce K. Patterson et al., “Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) Up to 15 Months Post-Infection”, bioRxiv, July 26, 2021, https://doi.org/10.1101/2021.06.25.449905. (Shows an association between “Long Covid” and persistence of spike protein in the absence of persistence of whole viable virus, again indicating that the spike protein alone is pathogenic.)
Hui Jiang and Ya-Fang Mei, “SARS–CoV–2 Spike Impairs DNA Damage Repair and Inhibits V(D)J Recombination In Vitro”, Viruses, October 13, 2021, https://doi.org/10.3390/v13102056. (Finds that the spike protein can enter the nucleus of cells and inhibit DNA damage repair and notes the relevance of this finding for spike-based COVID-19 vaccines.)
Sandhya Bansal et al., “Cutting Edge: Circulating Exosomes with COVID Spike Protein Are Induced by BNT162b2 (Pfizer–BioNTech) Vaccination prior to Development of Antibodies: A Novel Mechanism for Immune Activation by mRNA Vaccines”, Journal of Immunology, November 15, 2021, https://doi.org/10.4049/jimmunol.2100637. (Finds that spike protein induced by the Pfizer-BioNTech COVID-19 vaccine are carried by exosomes and circulate throughout the body, which helps explain the antibody response induced by vaccination.)
American Heart Association, “CDC investigating rare myocarditis in teens, young adults; COVID-19 vaccine still advised for all who are eligible”, Newsroom.Heart.org, updated June 23, 2021, accessed December 9, 2021, https://newsroom.heart.org/news/cdc-investigating-rare-myocarditis-in-teens-young-adults-covid-19-vaccine-still-advised-for-all-who-are-eligible. (Cited by MDHHS to support its own recommendation that children be vaccinated despite the risk of myocarditis. Cites VAERS data through May 31, 2021.)
Centers for Disease Control and Prevention, “The Vaccine Adverse Event Reporting System (VAERS)”, Wonder.CDC.gov, accessed December 9, 2021, https://wonder.cdc.gov/vaers.html.
Children’s Hospital of Philadelphia, “Questions and Answers about COVID-19 Vaccines”, CHOP.edu, reviewed by Paul A. Offit, MD on November 22, 2021, accessed December 9, 2021, https://www.chop.edu/centers-programs/vaccine-education-center/making-vaccines/prevent-covid. (This is the source cited by MDHHS to support its claim that the risk to children of myocarditis from SARS-CoV-2 infection is greater than from COVID-19 vaccines. CHOP does make that claim, but its primary sources cited do not support it.)
Guy Witberg et al., “Myocarditis after Covid-19 Vaccination in a Large Health Care Organization”, New England Journal of Medicine, October 6, 2021, https://doi.org/10.1056/NEJMoa2110737. (Cited by CHOP to support the claim that the incidence of vaccine-related myocarditis among males aged sixteen to twenty-nine is 5 per 100,000, or 1 per 20,000. Actually finds that the highest incidence of vaccine-related myocarditis occurred in males aged sixteen to twenty-nine years, at a rate of 10.69 cases per 100,000 persons vaccinated, or 1 per 9,355. The risk to children younger than sixteen was not assessed. This belies MDHHS’s claim that its own primary sources show that the risk is 1 in 50,000.)
Hannah G. Rosenblum et al., “Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021”, MMWR, August 10, 2021, http://dx.doi.org/10.15585/mmwr.mm7032e4. (Cited by CHOP to support the claim that the incidence of vaccine-related myocarditis in males aged sixteen to twenty-nine is 1 per 20,000. Does not even assess the risk in children, only adults, with highest risk among youngest group of males studied, ages eighteen to twenty-nine years, for whom there were 24.3 cases per million second doses administered, or 1 per 41,152, according to VAERS data. This again belies MDHHS’s claim that the risk is 1 in 50,000.)
Jeremy R. Hammond, “How You’re Being Lied to about the Risks of Getting a Flu Vaccine Annually”, JeremyRHammond.com, January 11, 2019, https://www.jeremyrhammond.com/2019/01/11/how-youre-being-lied-to-about-the-risks-of-getting-a-flu-vaccine-annually/#vaers. (See for sources on underreporting to VAERS.)
Jeremy R. Hammond, “Fact Check: WHO Scientist Caught Lying to Public about Vaccine Safety”, JeremyRHammond.com, February 11, 2020, https://www.jeremyrhammond.com/2020/02/11/fact-check-who-scientist-caught-lying-to-public-about-vaccine-safety/#Trust. (See for additional source on underreporting to VAERS, the AHRQ-funded study.)
Tegan K. Boehmer et al., “Association Between COVID-19 and Myocarditis Using Hospital-Based Administrative Data — United States, March 2020–January 2021”, MMWR, August 31, 2021, http://dx.doi.org/10.15585/mmwr.mm7035e5. (Cited by CHOP to support the claim that 59 out of every 960 COVID-19 cases, or 1 in 16. Actually finds that the overall risk of myocarditis among hospital patients diagnosed with COVID-19 is 0.146%, or 1 in 685, and for children under age sixteen 0.133%, or 1 in 752. In the video I said 751, but it rounds up to 752. A generous explanation for CHOP’s misinformation is that the author misinterpreted the relative risk of 15.7 times greater risk for patients diagnosed with COVID-19 than not those without COVID-19 as meaning that 1 in 16 COVID-19 patients had myocarditis.)
David A. Siegel et al., “Trends in COVID-19 Cases, Emergency Department Visits, and Hospital Admissions Among Children and Adolescents Aged 0–17 Years — United States, August 2020–August 2021”, MMWR, September 3, 2021, http://dx.doi.org/10.15585/mmwr.mm7036e1. (Finds that the incidence of COVID-19 among children aged five to eleven during the peak epidemic wave of January 2021 was 30.1 cases per 100,000 persons, or 1 in 3,322.)
Miranda J. Delahoy et al., “Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021”, MMWR, September 3, 2021, http://dx.doi.org/10.15585/mmwr.mm7036e2. (Finds that the cumulative incidence of COVID-19-associated hospitalizations among children aged zero to seventeen years was 49.7 per 100,000 children and adolescents, or 1 in 2,012, and for children aged five to eleven 24 per 100,000, or 1 in 4,167. Acknowledges that children with COVID-19 may have been hospitalized for other reasons and that the number of children who had severe outcomes was small.)
Tracy Beth Høeg et al., “SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children Ages 12-17: A Stratified National Database Analysis”, medRxiv, September 8, 2021, https://doi.org/10.1101/2021.08.30.21262866. (Specifically compares the risk of vaccine-related myocarditis with the risk of COVID-19-related myocarditis while taking into account the risk of being hospitalized with COVID-19 in the first place. Uses VAERS data. Finds that the risk for boys without comorbidities of vaccine-related cardiac adverse events is four to six times higher than their 120-day hospitalization risk.)
Ronald N. Kostoff et al., “Why are we vaccinating children against COVID-19?” Toxicology Reports, September 14, 2021, https://doi.org/10.1016/j.toxrep.2021.08.010. (Discusses many concerns about mass vaccinating children, including discussion of the toxicity and pathogenicity of the spike protein alone, the concentration of mRNA from vaccines in the ovaries, and the lack of human studies of the effects of COVID-19 vaccines on fertility. Also discusses the opposite standards of evidence used to classify “COVID-19 deaths” compared with vaccine-related deaths.)
Jeremy R. Hammond, “COVID-19: What You Need to Know about Fatality Rates”, JeremyRHammond.com, April 25, 2020, https://www.jeremyrhammond.com/2020/04/25/covid-19-what-you-need-to-know-about-fatality-rates/. (Video in which I discuss the overestimation of COVID-19 fatality rates and how CDC policy directives biased medical professionals to list COVID-19 on death certificates even if they didn’t die because of COVID-19.)
Food and Drug Administration, “Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers): Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19)”, FDA.gov, revised October 29, 2021, accessed December 9, 2021, https://www.fda.gov/media/153714/download. (Notes that data are insufficient to inform about the risks of vaccination during pregnancy and that there are no human studies assessing the effects of vaccination on fertility.)
Jessica Rose and Peter A. McCullough, “A Report on Myocarditis Adverse Events in the U.S. Vaccine Adverse Events Reporting System (VAERS) in Association with COVID-19 Injectable Biological Products”, Substack, November 2, 2021, https://jessicar.substack.com/p/a-report-on-myocarditis-adverse-events. (Using VAERS data, finds risk of vaccine-related myocarditis for children to be well above the expected background rate.)
Matthew Herper, “FDA scientists say benefits of Pfizer Covid-19 vaccine ‘clearly outweigh’ the risks for children ages 5 to 11”, STAT, October 23, 2021, https://www.statnews.com/2021/10/23/fda-scientists-say-benefits-of-pfizer-covid-19-vaccine-clearly-outweigh-the-risks-for-children-ages-5-to-11/. (Presents data from FDA analyses indicating that more than four times as many cases of vaccine-related myocarditis occur than are reported to VAERS, a rate of 1 per 5,556 boys aged twelve to fifteen vaccinated. Not the 1 in 50,000 claimed by MDHHS! Also reports FDA’s estimate that about 4,000 children, or 47,619 during periods of low transmission, need to be vaccinated to prevent 1 hospitalization. Given this plus the CDC estimate of 1 myocarditis case for every 752 hospitalized children with a COVID-19 diagnosis, we can see that for every 1 case of COVID-19-related myocarditis prevented, we can expect 314 cases of vaccine-related myocarditis.)
Pfizer, “VRBPAC Briefing Document”, presented to VRBPAC meeting on October 26, 2021, accessed December 9, 2021, https://www.fda.gov/media/153409/download. (Acknowledges trials not powered to assess risk of myocarditis in children. Shows 5,882 children need to be vaccinated to prevent 1 hospitalization for COVID-19. Claims myocarditis/pericarditis risk is 1 case per 47,619 fully vaccinated children. Given the CDC’s estimate of 1 myocarditis case per 751 children hospitalized, therefore 4,417,382 children need to be vaccinated to prevent 1 child from being hospitalized with COVID-19-related myocarditis. Therefore, according to Pfizer’s and CDC’s own data, for every 1 case of COVID-19-related myocarditis prevented, we can expect 93 cases of vaccine-related myocarditis. Nevertheless cites an Israeli study in NEJM to support the claim that the risk of myocarditis from COVID-19 is greater than the risk from its vaccine.)
Noam Barda et al., “Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting”, New England Journal of Medicine, September 16, 2021, https://doi.org/10.1056/NEJMoa2110475. (Cited by Pfizer to support its request for emergency use authorization from the FDA. An Israeli observational study finding receipt of the Pfizer COVID-19 vaccine to be associated with 3.24 times greater risk of myocarditis. Also claims that “SARS-CoV-2 infection” is associated with an 18.28 times greater risk of myocarditis then remaining uninfected, but they defined the incidence of infection as equal to the incidence of positive PCR tests among individuals who sought medical care, when it’s known that far more infections occur than reported cases indicate.)
Oyungerel Byambasuren et al., “Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: Systematic review”, PLoS ONE, April 2, 2021, https://doi.org/10.1371/journal.pone.0248946. (Finds that it is typical for there to be ten times more SARS-CoV-2 infections than reported cases.)
Food and Drug Administration, “FDA Briefing Document”, presented to VRBPAC meeting on October 26, 2021, accessed December 9, 2021, https://www.fda.gov/media/153447/download. (Acknowledges that the risk of myocarditis was never assessed for children aged five to eleven and that if COVID-19 incidence is low such as in June 2021, the risk of vaccine-related myocarditis is higher than the risk of COVID-19-related hospitalization for any reason for children [not just children diagnosed with myocarditis].)
